中文 | English
Return
Total: 73 , 1/8
Show Home Prev Next End page: GO
Author:( Yibing YANG)

1.Cost-utility analysis of capivasertib combined with fulvestrant in the second-line treatment of HR+/HER2- advanced breast cancer

Yang ZHANG ; Shuo KANG ; Xiaohui WANG ; Yibing HOU ; Xiangxia FU ; Huanlong LIU

China Pharmacy 2025;36(24):3073-3078

2.The status of violence against children in China, 2013-2021

Xin GAO ; Pengpeng YE ; Ye JIN ; Yuan WANG ; Yunning LIU ; Cuirong JI ; Xiang SI ; Xiaolei ZHU ; Yibing YANG ; Leilei DUAN

Chinese Journal of Epidemiology 2024;45(10):1371-1375

3.A Study of Policy Synergy in 71 Pilot Cities of DIP Payment

Xiangfei LI ; Yibing HAN ; Wei YANG

Chinese Health Economics 2024;43(5):37-42

4.A Study of Policy Synergy in 71 Pilot Cities of DIP Payment

Xiangfei LI ; Yibing HAN ; Wei YANG

Chinese Health Economics 2024;43(5):37-42

5.A Study of Policy Synergy in 71 Pilot Cities of DIP Payment

Xiangfei LI ; Yibing HAN ; Wei YANG

Chinese Health Economics 2024;43(5):37-42

6.A Study of Policy Synergy in 71 Pilot Cities of DIP Payment

Xiangfei LI ; Yibing HAN ; Wei YANG

Chinese Health Economics 2024;43(5):37-42

7.A Study of Policy Synergy in 71 Pilot Cities of DIP Payment

Xiangfei LI ; Yibing HAN ; Wei YANG

Chinese Health Economics 2024;43(5):37-42

8.A Study of Policy Synergy in 71 Pilot Cities of DIP Payment

Xiangfei LI ; Yibing HAN ; Wei YANG

Chinese Health Economics 2024;43(5):37-42

9.A Study of Policy Synergy in 71 Pilot Cities of DIP Payment

Xiangfei LI ; Yibing HAN ; Wei YANG

Chinese Health Economics 2024;43(5):37-42

10.A Study of Policy Synergy in 71 Pilot Cities of DIP Payment

Xiangfei LI ; Yibing HAN ; Wei YANG

Chinese Health Economics 2024;43(5):37-42

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 73 , 1/8 Show Home Prev Next End page: GO